Latest / Quantum Potential / Rewiring the Brain and Rethinking Pain with Craig Lindsley
Transcript
- 0:00The way I think about it in the lab is, you know, we want to kill the compound.
- 0:03You wanna kill the series.
- 0:04You wanna kill the target, you wanna kill the mechanism.
- 0:07Because, you know, if we can do that as well, it's great basic science.
- 0:10It lets people know where not to go, and allows us as a, as a collaborative, you know, community to focus on the targets that really could impact patients.
- 0:19Today I'm excited to welcome our guest, Dr. Craig Lindsley, a cutting edge innovator and scientist in neuroscience drug discovery.
- 0:26Dr. Lindsley is a leading medicinal chemist and neuroscientist with almost three decades of experience in drug discovery and development across industry and academia.
- 0:36He's a University Distinguished Professor of Biochemistry, Chemistry, and Pharmacology And the William K. Warren, Jr.
- 0:40Chair in Medicine and executive director of the Warren Center for Neuroscience Drug Discovery.
- 1:00Welcome to 'Quantum Potential,' a podcast dedicated to curiosity and discovery.
- 1:05My name is Cybele Raver, and I serve as the provost of Vanderbilt University.
- 1:09As a leader in higher education and as a social scientist, I believe that we can transform higher education for the 21st century.
- 1:16At my core, I am wildly curious about other people's work, whether it's in science, the social sciences, the humanities or the arts.
- 1:25This podcast gives us the opportunity to break open new ideas through discovery and creative expression.
- 1:38The Warren Center for Neuroscience Drug Discovery is a powerful hybrid academic and industrial drug discovery engine.
- 1:44And the work at the Warren Center, with Craig Lindsley leading, has advanced novel treatments for therapeutic areas around cancer, diabetes, obesity and neurological disorders like Alzheimer's, schizophrenia, Parkinson's disease, anxiety and pain.
- 2:00Dr. Lindsley is also editor-in-chief of the American Chemical Society Journal of Medicinal Chemistry, and his groundbreaking contributions have earned him induction into the American Chemical Society's Division of Medicinal Chemistry Hall of Fame.
- 2:13The Royal Society of Chemistry, the National Academy of Inventors, among many, many other accolades.
- 2:19Dr. Lindsley continues to push the boundaries of drug discovery to help people suffering from multiple medical challenges across the United States and across the world.
- 2:29Craig, let me begin by saying that we are so grateful for all the work that you're doing.
- 2:34Really exciting to have you today.
- 2:36Well, thank you so much.
- 2:37It's great to be here.
- 2:37So today we're talking about cutting-edge neuroscience research— breakthroughs that could change the way we treat major threats to our health and well-being, like schizophrenia, Alzheimer's and chronic pain.
- 2:50Craig, before we dive into your work, discovering new medicines to treat those incredibly debilitating conditions, just help us understand a little bit more about the brain.
- 2:59Specifically, how do we think about the way in which Alzheimer's disease affects roughly 7 million people with no known cure?
- 3:07Many of us listening have a family member or a loved one who suffers from these terrible neurodegenerative diseases, but there's a lot we don't understand about the brain.
- 3:16What's going on with Alzheimer's and Parkinson's?
- 3:18What's actually happening in the brain?
- 3:21Well, it's, it's, it's very complex, and it, it really kind of goes back even to the way we think about oncology now, and personalized medicine. Everyone's Alzheimer's symptoms can, may appear the same, but the etiology of the disease can be very, very different.
- 3:33So what we do know is you see severe loss in multiple signaling pathways.
- 3:38We see degeneration of the brain, we see loss of brain mass, aberrant signaling.
- 3:42And so there's never gonna be, I think a, a, a magic bullet—one, one drug that's gonna cure everything.
- 3:48And even now as we think about clinical trials, we really have to think about palliative care and just improving cognition and keeping patients out of assisted care facilities.
- 3:58And so the easiest thing right now to work on is behavioral disturbances and, and increasing cognition and working memory by modulating different receptors that are downregulated in the disease.
- 4:07Great.
- 4:08I mean, I think you talk a lot about positive allosteric modulators, right?
- 4:13These idea of these PAMs, and you also talk about negative allosteric modulators.
- 4:18What is that?
- 4:19What is a modulator in the brain?
- 4:21How does that work in terms of signaling?
- 4:22Yeah, so a lot of times what you'd have, you'll have is a receptor that's either has a loss of function or a gain of function.
- 4:27So we want to turn it down or turn it up.
- 4:29And historically, especially with a lot of families of receptors, people use what we call an agonist or an antagonist, which would directly activate or directly inhibit the receptor.
- 4:39And this is a receptor on neurons?
- 4:42On neurons.
- 4:42Mm-hmm.
- 4:43And it's affecting how the, the neuron takes up or doesn't take up...
- 4:48Neurotransmitters.
- 4:49...neurotransmitters like dopamine, right?
- 4:51Mm-hmm.
- 4:52Acetylcholine and things like that.
- 4:53So, the problem with agonists is they bind at a, a very conserved site across a family receptor, so you typically get poor selectivity.
- 5:01So if we think about the drug that was just approved by BMS—Cobenfy, which is a, a muscarinic agonist— it activates all five subtypes.
- 5:09And so they have to coadminister peripheral antagonist with it to avoid GI side effects and other ... other problems.
- 5:16What we've done is we target the allosteric sites that are not conserved.
- 5:20And just to slow down what is an allosteric site?
- 5:23Uh, it just means other.
- 5:24Okay.
- 5:24So it's a site other than where the native neurotransmitters bind.
- 5:28And so by doing that, we get amazing selectivity for one out of a family of maybe five different subtypes.
- 5:34And so we can only activate the receptor of interest, not all these others that could cause adverse effects.
- 5:40And then a PAM, the way to think about it is when a positive allosteric modulator binds to a receptor, it doesn't do anything on its own, but when the native agonist like dopamine or acetylcholine binds, you get a heightened response.
- 5:53And so it's more like a dimmer switch or changing the gain on a receptor versus just turning it on or off like a light switch.
- 5:59Because with, as you go into these diseases where you're gonna be doing chronic daily maintenance therapy for 20, 30 years.
- 6:05Right?
- 6:05When you just turn receptors completely on or completely off, they can down- regulate, they can be internalized, and then after a while you lose efficacy.
- 6:13So having something that just turns up the gain, keeps everything in its normal physiological state.
- 6:18Right?
- 6:18So somebody with Parkinson's is gonna live with Parkinson's not just for two years or five years, or even 10 years, but potentially 20 or 30 years.
- 6:26So you have to find a medicinal solution that they can utilize over that entire time that essentially doesn't burn out or max out the system.
- 6:35Right.
- 6:35So for Parkinson's, for example, you know, the, the, the standard of care since the sixties has been L-DOPA—various variations of, of L-DOPA to, to increase dopamine.
- 6:45But being an agonist, what happens is you get the on-off periods and wearing off effects, and then you develop dyskinesia'cause you're just, you're hitting the receptor so hard and keeping it on for so long.
- 6:55You have all types of, um, you know, negative side effects.
- 6:58Amazing.
- 6:59And I think that sense that I read from your papers that you're managing and, uh, really monitoring all the other ways in which that particular medicinal solution might be negatively affecting, whether it's kidney or, you know, other portions of the brain, that you have to have this incredibly precise, uh, way of targeting a specific, location, uh, at a specific time with a specific dose for a specific period of time so that that dimmer switch isn't drastically cranked up or drastically cranked down.
- 7:33That's correct.
- 7:33Amazing.
- 7:34Just incredible to think about the precision with which you have to actually do that.
- 7:39Tell us a little bit about the ways in which, uh, restoring healthy brain function is possible.
- 7:44When you think about the outcome that you're trying to achieve with somebody with Alzheimer's as you develop this particular set of medical solutions, these particular chemicals that could serve as drugs, what are you shooting for?
- 7:58What's the hope?
- 7:59Well, yeah, the way we, uh, that we think about it a lot is, you think about the patient and the patient needs, but a lot of times with severe brain disorders it's actually harder on the families and the caregivers than the actual patient, 'cause they may not really be aware of everything that's going on.
- 8:14So we always, we, we really think about what can we do to make quality of life better for the patient and their families.
- 8:19So that's kind of the guiding principle.
- 8:21But again, if you think about so many of these brain disorders, if you have a circuit, just like a circuit in a light switch, right?
- 8:27If you turn it on all the time, it's gonna burn out.
- 8:30It's not gonna work very well.
- 8:32And if you just potentiate it.
- 8:33If you just modulate function and increase the gain just a little bit, that can actually, in, in certain cases, not only can you get palliative benefit on cognition, but you can actually start to have disease modification because you're not burning out all the downstream receptors that are just getting, you know, constantly being activated.
- 8:51So a lot of the mechanisms we work on and targets with PAMs, there's data suggesting they're neuroprotective and neuro restorative over time.
- 8:58Mm. Amazing.
- 8:59So you're not simply just trying to ease the progression of a disease like any neurodegenerative disease, but in Alzheimer's or other forms of dementia.
- 9:09You're actually trying to support the brain in terms of the way in which that set of pathways may be, sort of assaulted by that neurodegenerative process that you're trying to keep people in a healthier state for a longer period of time.
- 9:22Correct.
- 9:23Amazing.
- 9:23But for a clinical trial you have to go for just palliative, you know, an improvement in cognition 'cause you can't run a 10-year outcome trial.
- 9:29But with collaborators in Scotland, Andrew Tobin, we did a a, an almost two-year-long study with one of our compounds in mice.
- 9:37And you could show that you increased lifespan significantly in performance.
- 9:41And so it seems like it's possible.
- 9:43Incredible.
- 9:43And in terms of cognition, is it about restoration of memory or preservation of memory so that people can remember their loved ones and the make, you know, match names and faces as people come in the door?
- 9:56Is it remembering things like where they put their keys or whether they, um, just gave somebody, you know, a large chunk out of their savings account?
- 10:04Or is it, uh, more on the behavioral side?
- 10:06Well, it's all those. Uh, we, we'd like to make ... have, have people have better memory— short, long-term memory—but it's also ... a lot of the things we work on are executive functions.
- 10:14So you can remember "I put my keys here 'cause I need to go here next," and those kind of things, which, you know... Even in schizophrenia, people typically think about just the hallucinations, but there are massive cognitive deficits, which is why even folks that are on atypical antipsychotics, they can't seem to really work.
- 10:30They don't, they can't integrate in society, and it's because of the massive cognitive disruptions.
- 10:34Yeah.
- 10:35Making decisions.
- 10:36They can't, yeah.
- 10:36Yeah.
- 10:37Making key, key decisions that are wise rather than driven by, sort of, the more appetite or emotive, emotional-driven, uh, mechanisms.
- 10:47Incredible.
- 10:48Walk me through the drug discovery process.
- 10:52I think the extent to which I loved in reading your papers, you know, you provide a diagram for each one of those chemical compound variants with just tiny changes in what looked like changes in covalent bonds at the top of a ring, or a change in atomic structure, or a change in the way that ring was oriented, whether it was oriented to the left or to the right.
- 11:13So it strikes me for, as a person who doesn't know your field, that you run these large number of variants through these successive set of gates to try to determine which of those many, many keys might fit the lock?
- 11:26Is that the, the right analogy, Craig?
- 11:28Yeah, that's, that's really accurate.
- 11:30Yes.
- 11:30I, I don't know if everyone realizes that a drug discovery program from start to getting a compound approved by the FDA and launching and actually having it available in a pharmacy is about a 15-year process.
- 11:44Incredible.
- 11:44Um, the work we'll do in the laboratory will typically make maybe ten to twenty thousand molecules.
- 11:51And there's iterative rounds of chemistry, biology, drug metabolism.
- 11:56'Cause it's not just on target potency and selectivity, but then, can you ingest the molecule?
- 12:01Does it dissolve?
- 12:02Does it get into the bloodstream?
- 12:03Does it cross the blood brain barrier?
- 12:04Does it get to the location of the brain where you need it to be?
- 12:06And does it do so without any kind of toxicological findings?
- 12:11And so the As in, it might be helpful in one regard, but negatively consequential in another.
- 12:17It might actually, you know...
- 12:17241 of, of, of liver toxicity,'Cause this is long term cardiovascular toxicity.
- 12:27But you know, it's typically two to five years in the laboratory.
- 12:31And then the next 10 are all under the FDA guidance for the, uh, investigational new drug, uh, enabling studies.
- 12:38Then phase one where we're in healthy volunteers.
- 12:40Then phase two where you're in patients.
- 12:42And then phase three where you do a much larger multicenter trial with heterogeneous patients, uh, to make sure it works.
- 12:49So it's a, it's a long process and you go from ten to twenty thousand compounds down to one.
- 12:54And then still, when once you're in clinical development, there's about a 95% failure rate'cause there's just things you can't predict— idiosyncratic tox, and other, other kind of things.
- 13:04But if you imagine from a business perspective, if you are building cars or televisions and 95% of your cars got scrapped on your, uh, assembly line, it's not a very good business model.
- 13:13It's very, it's very, very hard.
- 13:14Very, very costly in terms of both, uh, obviously, all the things that go into that, including many, many mice as I read.
- 13:23Mm-hmm.
- 13:24A lot of animal models.
- 13:25A lot of animal models, a lot of reagents, a lot of, uh, chemistry, but also a lot of people.
- 13:30Mm-hmm.
- 13:31So, you know, before we can go into healthy volunteers, we have to do toxicology studies in, in, in a variety of different animal species to make sure it's safe before you go into humans.
- 13:39I, I think it's a really interesting story.
- 13:41I dunno if you know this one.
- 13:42Um, why the FDA got started?
- 13:44No.
- 13:44So, uh, right after World War I—back then there were no labels on anything.
- 13:49And a lot of drugs and, and medications just had cocaine in them and, and things like that.
- 13:53Wow.
- 13:54But after, after World War I, there was a, uh, a lot of bacterial outbreaks in the U.S. from people coming back.
- 14:00One company took an antibiotic that wasn't soluble.
- 14:03So they dissolved it in ethylene glycol, which is antifreeze, and added raspberry syrup to it, and directly went and gave it to, uh, thousands of children.
- 14:12Wow.
- 14:12Uh, about 450 of them died from ... immediately from renal toxicity, kidney failure.
- 14:17Okay.
- 14:17So that was a medical advance, quote unquote...
- 14:20Mm-hmm.
- 14:20...generated by a corporate entity that was completely unregulated and...
- 14:25There was no regulation at all.
- 14:26So then they, they started the Food, Drug and Cosmetic Act, which said you have to first test this in an animal.
- 14:31When they tested that same formulation in animals, the animals all died.
- 14:34So had they done this first, it would've saved all these children.
- 14:37So then that led to the FDA and drug safety and drug monitoring.
- 14:41And so now before something moves into the clinic, it is, it is very, very well vetted.
- 14:45Yeah.
- 14:46And I love the, layering of all of those processes.
- 14:50You know, could you make the chemical compound at scale, you know, that you started with. Is this even something that is replicable?
- 14:57Is this something that we could actually manufacture?
- 14:59That's, that's another problem.
- 15:00So in the laboratory, you're making milligram quantities, and maybe you'll make a gram at the end of the day, which isn't really that much material.
- 15:07There's two grams of sugar in a Coke.
- 15:09So, you know, make about a, a gram of material.
- 15:11But then when you go into the clinic, you're making 10 kilograms, and so you have to develop entire process plants that just make your, your drug.
- 15:19And a lot of times, uh, there can be failures, there can be impurities you can't get out.
- 15:23The cost of intermediates can go up.
- 15:25There, there's all kinds of kinds of issues.
- 15:27So molecules can fail in so many different places along that, that continuum.
- 15:32So fascinating.
- 15:32So you have this, you know, chemical set of constraints— can you even make this stuff you're trying to test, right?
- 15:39Mm-hmm.
- 15:39Um.
- 15:40Can you make it well? Is it pure?
- 15:43Is it, does it have other stuff hanging onto the edges of it, essentially that might be toxic?
- 15:49And then, is it, uh, essentially targeting the, the actual regions, the brain regions that you hope, uh, through both mouse models and rat models, other there animal models to even see that it, it is achieving even close to what you're hoping to achieve?
- 16:05I love that you even include behavioral models that you um, had this, uh, way in which you would try to essentially instantiate schizophrenia-like symptoms or Alzheimer's-like symptoms in mice and see whether the candidate chemistry that you were developing, um, was demonstrating that kind of behavioral impact.
- 16:26Can you say a little bit about how the worlds of your labs work?
- 16:29Sure.
- 16:30Obviously, you know, one side, the beaker and reagent side, versus another side of your lab—the, um, you know, animal model side— must be an incredibly vibrant, active group of people, but not everybody's doing the same thing.
- 16:43Sure.
- 16:44Drug discovery is probably the, the greatest single example of big team science.
- 16:48So you have people who are subject matter experts in different areas, but then they all collaborate and integrate and just work seamlessly across the, the, the task.
- 16:56So the chemists make the small molecules, they synthesize them, purify them, characterize them.
- 17:02Then the molecular pharmacologists test them on in cell-based assays— are we potentiating the receptor, we want to or inhibiting the receptor we want to?
- 17:10And then they go into our drug metabolism group, which does in vitro work in cells first to see, is the compound highly bound of plasma proteins or not?
- 17:19Does it have stability in, in, in rat plasma?
- 17:22Does it get into the brain?
- 17:23We do in vivo studies.
- 17:24Is it, uh, what's the pharmacokinetics?
- 17:26Is it orally bioavailable— can you, can you take the pill and it gets to where you want it to go?
- 17:30And then on campus with Carrie, Dr. Carrie Jones, she does all of our neuro behavior.
- 17:35And so for every program we work on, we have a primary pharmacodynamic assay.
- 17:40It could be, we could be doing a pharmacological challenge, we could be inducing a schizophrenic- like deficit or a Parkinsonian- like deficit with a, with a drug.
- 17:49And then we try to reverse that.
- 17:51Or in a lot of cases we have genetic mice.
- 17:53They actually carry human mutations that we know are associated with the disease, and we see if our molecules can reverse those phenotypes.
- 17:59Incredible.
- 18:00So, And then it's just a constant feedback loop.
- 18:02Right?
- 18:03So what you learned at that later stage, you then carry back to your chemist to say, "Okay, we actually need to utilize that other variant of Of that compound because this is, is yielding not quite what we hoped." And that's why, and like you see in these tables, sometimes the, the, the changes in the molecule are very, very subtle'cause we're just trying to fix a drug metabolism liability, a solubility liability, trying to decrease exposure.
- 18:25And a lot of times the changes are really minute, you know?
- 18:29You know, not always really big changes to get to get where you need to go.
- 18:32Amazing.
- 18:32And I guess what it leads me to realize is this incredible work that you're doing to keep me safe, right?
- 18:39That you know, when I, or anybody that I love or anybody in our world or anybody in our community takes a medicine that we purchase at the pharmacy, that there is 10 to 15 to 20 to 30 years of all of that work going to ensure that that little pill is not just manufactured correctly, but that what that, that those active ingredients, those active molecules have been tested against so many different challenges, um, that have utilized so many different, uh, hands on deck, so to speak, to ensure its safety.
- 19:12How do you maintain that level of clarity and commitment and energy?
- 19:18Knowing that you're not gonna see a, you know, a result for 95% of what you're doing and, um, that it's gonna be years.
- 19:27You know, it's just the challenge of doing it.
- 19:28Yeah.
- 19:29I think especially working in brain health, it's the hardest, right?
- 19:32These are daily maintenance therapies for 20, 30 years.
- 19:35Getting compounds that you're orally, you know, can be taken orally and get to the brain is, is, is probably one of the hardest things to do.
- 19:42You know, oncology drugs are acute.
- 19:44Bacterial.
- 19:45Acute, viral, acute, you know, so this is really a challenge, but it's, um, I, I think everyone that works at the Warren Center just loves the challenge of it, and there's always the chance that your compound's gonna make it. So, you know, it's, it's, it's just a different mindset.
- 19:59Does it have the, that sort of wonderful Vanderbilt, SEC "I love a challenge and I'm particularly competitive." Does it, are, are you, are you trying to beat another lab?
- 20:07Is there a sense of ... Oh yeah.
- 20:08You know, sort of race to the finish or?
- 20:10So I, I think one of the greatest things about doing what we're doing here at Vanderbilt versus at, when I was say in industry at Merck— when I was there, if we were working on a program and we did not develop the drug, we failed, and it was all viewed as a massive failure.
- 20:24Here, we have so many examples of where we started doing basic science around targets, uh, developed tool compounds, validated the targeted animal models.
- 20:36And that led other pharmaceutical companies to start programs, and they all cite our papers and our patents.
- 20:41Mm-hmm.
- 20:41And, and, and that's actually how we got some of our deals— companies have come to work with us because of our, our basic science papers on things.
- 20:47But, like, some of the programs that are in the clinic right now, we actually beat the big pharma 'cause we invested more time in really understanding all the little caveats around the target and what's necessary, so...
- 20:57I love that.
- 20:57A lot of things like that, you know.
- 20:58But it's great because at the end of the day too, is if if the science we do here at Vanderbilt inspires other companies to start the same programs—whether we get the drug out at the end of the day, it's a Vanderbilt drug, or if it's a Merck or a Pfizer drug—but the patients benefit?
- 21:12It's awesome.
- 21:13I mean, I, I love, yeah.
- 21:14The impact of that is just amazing.
- 21:15Right.
- 21:16I love the impact, and I really love the idea that early-stage failure, quote unquote, could either be viewed as failure or it could be viewed as catalyst, right?
- 21:26Mm-hmm.
- 21:26It could be viewed as early-stage breaking open of something that we didn't know or that is disconfirming, and that inspires actually more of us to jump in and try to tackle it, right?
- 21:37Sure.
- 21:38And you know, I think that the way we approach things, too, is, or the way I always approach things, is a little, is a little different.
- 21:42There are so many possible targets we could work on.
- 21:44So many.
- 21:45Uh, and, and with bioVU and, and other genetic, we're getting so much input on genetic dysfunction that's leading to certain diseases, which gives ideas for targets to work on.
- 21:55And so, the way I think about it in the lab is, you know, we want to kill the compound.
- 21:59We wanna kill the series.
- 22:01You wanna kill the target.
- 22:02You wanna kill the mechanism.
- 22:04Because, you know, if we can do that as well, it's great basic science.
- 22:07It lets people know where not to go and allows us as a, as a collaborative, you know, community to focus on the targets that really could impact patients.
- 22:15Cool.
- 22:15So when you say kill the compound, you mean basically scratch it off the list?
- 22:19Well, let's find what's wrong with it.
- 22:20What, where, what, where is it deficient?
- 22:22If you let, let's, let's do every experiment we can to try to knock the compound out of the running.
- 22:29And if you do, if you do everything you possibly can and you can't do that, that's how we get search some of these molecules that then moved into human testing because we did everything we could to, to prevent it from going forward, and we still made it.
- 22:39Wow.
- 22:39Wow.
- 22:39So that's just to put a, to circle back then, you know, talk about keeping us all safe.
- 22:46The, the med that we're taking is the winner after all those other candidate chemical compounds have been knocked off.
- 22:56So it wasn't like, you know, the first one outta the blocks.
- 23:00Oh, no, no.
- 23:01It's the absolute reigning winner after so many forced, kind of, uh, comparisons and challenges.
- 23:08And, and I think if you look over the last 30 years, there's been such a great interaction between industry, academia and the FDA.
- 23:16And every time they start to identify drugs that cause liver toxicity or cardiovascular toxicity, you know, industry and academics partner together, they figure out what that cause is—and now that's part of the testing cascade.
- 23:28Uh, so we don't have, you don't see drugs being recalled anymore for drug-induced liver injury or for cardiovascular or QT prolongation,'cause we've, that, that, that's, that that communication loop just gets, uh, amplified and everybody goes and addresses the problem and figures it out, and then...
- 23:45Awesome.
- 23:45You know, there could be something else looming we don't know about yet, but you know, we can, we can definitely eliminate all the known knowns and, and...
- 23:51Got it.
- 23:51...and bring safe drugs forward.
- 23:52It's, it's stitched into the process instead of being something that we hope doesn't happen down the line.
- 23:57You know, I was thinking a lot about that, and I just wanna first note that synergy between industry and the federal government and research labs like yours at Vanderbilt.
- 24:08When I look at this paper, Craig, I notice right under the title there are 26 authors, right?
- 24:15So it's not you claiming "ta-da! a new drug!" Mm-hmm.
- 24:18Right?
- 24:19It's you and 25 other people.
- 24:21Tell me about this amazing team.
- 24:24Well, yeah, so this is, again, like I mentioned, this is big team science.
- 24:27So anytime you work on a program, uh, like this, M1 Pause Ulcer Modulator program for Alzheimer's schizophrenia.
- 24:34You've got a team of six, seven medicinal chemists working on it.
- 24:37You've got two molecular pharmacologists running the assays.
- 24:40You've got a team of three or four drug metabolism scientists, two or three behavioral pharmacologists, and then we have the toxicologists.
- 24:48Because with this program, this was one where the Warren family, uh, the first gift they gave us was to provide the funding to take this compound through IND-enabling toxicology.
- 24:58Uh, which then poised us with Paul Newhouse to get Alzheimer's funding to go into the phase one, which was run here at Vanderbilt.
- 25:04Amazing.
- 25:04So it's a, it's, it's, it's, it takes everybody working together and, and, and I mean, the integration, the, the communication, it's, it's, it's it's like nothing else.
- 25:13It's great.
- 25:14And is that largely mid-career scientists?
- 25:17Is that junior scientists?
- 25:18Is that undergraduates and graduate students?
- 25:20Is that postdocs?
- 25:21Who, who are those toxicologists and those behavioral pharmacologists?
- 25:27What stage of career are they?
- 25:28So these are usually, you know, so this would be like Dr. Carrie Jones and, and folks in her lab.
- 25:32So they're, they're more senior scientists,'cause this is really tricky stuff.
- 25:36Yeah.
- 25:36When a program becomes a real drug discovery project where we're developing IP and, and really going toward a clinical candidate, then it's really just the staff scientists in, in the Warren Center.
- 25:46So these could be junior medicinal chemists, senior medicinal chemists— same thing on the pharmacology side.
- 25:51Uh, in terms of toxicologists, we typically go to CROs for that 'cause we don't have internal toxicologists.
- 25:56Sorry, what's a CRO?
- 25:57Oh, uh, contract research organization.
- 25:59Got it.
- 25:59But in the early, the earliest genesis of all these programs where we're trying to develop cell lines and make the first tool molecules and target validation, those have always been done on RO1s or other types of federal funding or, or, or foundation grants.
- 26:13And this, uh, foundation of all this is done with grad students, postdocs, undergrads.
- 26:18You know, think about it, too, for training for students to be able to, to walk through, you know, chemistry, pharmacology, drug metabolism behavior, and see something that they started on going through all those iterations...
- 26:30Yes.
- 26:30...and validating a target.
- 26:31It's.
- 26:32It was, it, it's been really phenomenal training for those students, and now they're leaders in industry and academics that have been worked away.
- 26:37Super inspiring, right?
- 26:38They go on to those incredibly important next steps in their career.
- 26:42Because they're not just, you know, like, you know, you can get really niched, you know, I, like, I could just say, "I'm, I'm just a medicinal chemist, and I don't do anything else." But the exposure you get and the, the access to all this other things— people start thinking differently, asking questions, and, you know, they become really holistic drug discovery scientists, not just a single discipline.
- 27:00Makes total sense.
- 27:01But, and I've loved walking through your lab.
- 27:03I've loved seeing the incredible energy.
- 27:05It's, it's very calm, but it's also and very focused, but there's also very high energy.
- 27:09There's a lot going on.
- 27:11There's a lot going on.
- 27:11Um, you know, it's really impressive.
- 27:11And I think a lot about the way in which you're contributing not only to the nation's health, but to the nation's economic strength, right?
- 27:21You know that those 26 people are supported by probably what, another 40, uh, lab technicians.
- 27:28Mm-hmm.
- 27:28And, um, everybody from the building custodian to the real estate person that rented you the research space, right?
- 27:35That I think about how you are contributing, whether it's in Franklin, Tennessee, or for the state of Tennessee or for the region, to this, sort of, massive endeavor, which is actually a key strength of, uh, our economic competitiveness worldwide.
- 27:51It really is.
- 27:52I mean, we're creating a lot of, uh, economic growth in the, in the, in the area.
- 27:55And the Warren Center is really probably the only biotech in, in Nashville, in Nashville area.
- 28:01And it functions like a biotech.
- 28:02Yeah.
- 28:03And clear from the list— I loved that you gave due credit for each of your authors in terms of who they are, and in the back of the article, a couple of them are from pharmaceutical firms, uh, and the funding is partnered with Acadia Pharmaceutical.
- 28:19That level of industry partnership, is that typical of the work that you do as a scientist that's discovering new medical breakthroughs?
- 28:26Yeah.
- 28:27So for us in the Warren Center, you know, we can get federal funding and foundation funding to do all the discovery and, and get compounds to the point of where they're ready to go into IND enabling studies.
- 28:36But then those costs just are exponentially grow.
- 28:39So, so far we've had 37 collaborations with big pharma and biotech, and they typically will come in and they'll sponsor research to get to the clinical candidate and backup compounds.
- 28:49Then they carry the burden for the IND-enabling studies and the clinical development.
- 28:53Got it.
- 28:54So right now we have four compounds in clinical development.
- 28:58Our a spin out company we had, Appello, they just got their next funding round, and they're gonna be going into phase two— so our first efficacy trial in actual patients. The other three are phase ones in healthy volunteers, but there's six other programs right now in IND-enabling studies that should be in the clinic...
- 29:14I'm sorry, just slow down so that everybody, including me, IND-enabling means?
- 29:19Oh, sure.
- 29:19Uh, so once you have a compound that leaves the laboratory, before you can go into healthy volunteers, we have to do what's called investigational new drug application.
- 29:29And so there's toxicology studies we have to do, and this is where, again, based on what happened with those children in the, in the 1920s, we have to thoroughly vet our molecules for toxicology and safety and multiple preclinical species, very rigorous.
- 29:43Those results go to the FDA, who review them, and they can give you permission to proceed into a phase one trial, or they can give you a clinical hold or they can just deny you if they don't feel the safety is is where it needs to be.
- 29:55So it may be 12 years of work, then you hit this key key gate, this key moment in the finding of the key into the lock...
- 30:03It's the...if that tumbler can turn or not.
- 30:06It's the longest 30 days of your life.
- 30:08So once you submit the IND application the FDA, they have 30 days to review it and respond and either say you can proceed to the clinic or not.
- 30:16And that, that's a very long month.
- 30:18Wow.
- 30:18And does the lab, you know, toast with a glass of champagne when the answer is yes?
- 30:23How do you ... We have, we have done that.
- 30:24That's, that's a, that's, that's a big accomplishment.
- 30:26Um, I mean, it must just feel incredibly gratifying after those intense months and years.
- 30:32It is, you know, because when I was at, when you're in industry, that's just, you expect to do this kind of work all the time.
- 30:39And, and that kind of level of, of, you know, things working out is just expected.
- 30:44When we first started the center, we really were thinking more about just validating targets and not really translating things all the way into the clinic.
- 30:52And the fact that now, you know, the center's delivering on a pipeline, and we just, it just, there's all the, this momentum and things just keep progressing and, and, and going to the next milestone— it's amazing 'cause we honestly didn't think we would have gotten to where we are.
- 31:09So it's incredible.
- 31:09It's just really fantastic.
- 31:10Incredible.
- 31:11I think many of us don't realize, or can't necessarily access the image, that you are both, you know, bench scientist and CEO, right?
- 31:23That you are both discovering new compounds and running this massive, huge enterprise that has all these people that are contributing not just to science, but to, um, the economy.
- 31:39It's just a, a, a kind of profound, um, sort of double role that I can now understand.
- 31:45Do, do you have a favorite role?
- 31:47Do you like being the CEO more than the scientist or the scientist more than the CEO?
- 31:52You know, doing this in academics is interesting 'cause you are, you're like a CEO, a CSO, a CFO, you're the IP attorney, you're doing all, you're doing all these different things.
- 31:59Um.
- 31:59Cleaning the kitchens...
- 32:00Yeah.
- 32:01Uh,...the sink when the, You know, talk, you know, trying to negotiate contracts with people, reviewing terms.
- 32:06I mean, you're doing so many things, right, and it's all essential, and it has to be done to keep progress moving ... programs develop.
- 32:12But there's something about when you were a bench chemist and you designed a molecule, you made it, and then that became the compound that moved forward.
- 32:19There was just something really rewarding about that.
- 32:22And it's harder when you take yourself out of the laboratory and you're doing all the, the, the higher- level things that are essential...
- 32:27Yeah, yeah.
- 32:27...but you're not, you don't have that tangible reward of, you know, that's my compound.
- 32:33Further from the bench or further from the actual testing of the animal model, et cetera.
- 32:39Yeah.
- 32:39Yeah.
- 32:40Now feels like a good time for us to take a quick break.
- 32:43We'll be right back with the next segment on pain management.
- 33:03So welcome back, Craig.
- 33:04It's been so fascinating to talk about all your multiple roles and an incredible power of, uh, medicinal chemistry to address, uh, issues like Alzheimer's and Parkinson's.
- 33:13I'd love to turn right now to some of your recently published groundbreaking work on discovering drugs that might dramatically change the way we treat pain. As we've seen from the opioid crisis in this country, we desperately need better alternatives to treating pain.
- 33:28Can you tell me a little bit about your work in this area?
- 33:30Sure.
- 33:30Um, so we've been working in pain for, for quite some time.
- 33:33A lot of our targets cross over across multiple therapeutic areas, but with Ono Pharmaceuticals, for example, we've had a 12-year collaboration with them, and it's always about non-opioid analgesia.
- 33:45We, after all the, the opioid crisis, we're always looking for nonopioid medication, so, with Ono, uh, we've been working on ion channels— it's a different type of receptor that can, that conducts potassium ions across membranes.
- 33:58And so we, uh, developed the first Trek one inhibitors or activators, and they're very efficacious in multiple models of pain and they don't have addictive liability, unlike opiates.
- 34:09And as I read the paper, you screened 20,000 candidates to find those Trek one and Trek two, and...
- 34:18To find one uh, one lead compound.
- 34:20To find one lead compound.
- 34:21Only one lead compound.
- 34:22You screened 20,000 other candidates.
- 34:25Mm-hmm.
- 34:26Amazing.
- 34:27Okay.
- 34:27So you, how long did it take to screen 20,000 candidates?
- 34:31Oh, well these, uh, the screens are fairly high ... a few months.
- 34:34Yeah.
- 34:34Okay.
- 34:34So a few months, you narrow it down.
- 34:36You narrow it down.
- 34:37And then that paper was sort of like a horse race as I could read it, at least, that you're really challenging one candidate against another to try to understand which is more efficacious.
- 34:48Mm-hmm.
- 34:49So it is always gonna be subtle things with, with potency, efficacy, pharma exposure in the brain.
- 34:56Uh, or can you get efficacy in pain without having to get into the brain?
- 34:59The, the, the root, uh, dorsal horn, there's a lot of pain sensory neurons there. But we also had some large grants from NIDA to work on, on different pain targets.
- 35:09We, one of our mGlu5 NAMs was a, uh, was a HEAL grant.
- 35:14Compounds efficacious in multiple types of pain.
- 35:17There's, there's lots of different, very forms of pain, and, um, that's looking really good.
- 35:21We're in discussions to license that program now, but again, it's, it's always, you have to do all the, uh, uh, addiction liabilities and abuse liabilities studies to make sure that you're not just making an opiate by another name.
- 35:33There you go.
- 35:33So, so we have to do those kinds, all that work up front.
- 35:36And is the screening as, as rigorous or even more rigorous than what you just described for the previous rounds in terms of the IND?
- 35:44Yeah.
- 35:44Just it, it, it, it's, it's much more challenging.
- 35:47Again, pain medications have to really be exquisitely safe and clean and, and, uh, non-habit-forming and those kind of things, which is ...
- 35:54I love that phrase "exquisitely...
- 35:55For others you don't have to.
- 35:55For other, other targets, you don't have the same, the same liabilities.
- 36:00Yeah.
- 36:00Yeah.
- 36:01And then, you know, you mentioned that NIDA supports that, that's the National Institute of Drug Abuse.
- 36:07Abuse.
- 36:08Good.
- 36:09Okay.
- 36:09So I know my federal agencies, just barely.
- 36:12You know, that's been in the news a lot because of the National Institutes of Health...
- 36:16Mm-hmm.
- 36:16...experiencing, uh, such dramatic changes in, uh, uh, sort of their ability to, uh, distribute funding.
- 36:23What does that mean when the National Institutes of Health has has to curtail or, uh, limit, um, its ability to disperse funds to labs like yours.
- 36:34Yeah.
- 36:34It's, it's, it's really—not to be overly dramatic—but it's very crippling,'cause if you, if you look at the history of the center, 95% of the programs we've worked on started with federal-funded RO1s and UO1s ones and things of that nature.
- 36:47And RO1s, just for the folks listening, that's a, that's a starter grant, right?
- 36:51That's a, a, a basic five-year starter grant.
- 36:53You have an idea, a concept, you know, in our case, maybe it was, we, we think we can develop selective M1 positive allosteric modulators, and we think they're gonna be good to restore cognition.
- 37:04And, uh, that gets funded, and then that gives us the money to develop the cell lines, make those early tool molecules, do the target validation.
- 37:12And tell me just a little bit, while we're on that point—that early funding is a risk you take as a scientist, and it's a risk certainly that the federal government takes in terms of trying out a new idea.
- 37:24Is that a risk that a pharmaceutical firm would ordinarily take, because they're so needing to meet the bottom line, right?
- 37:31As you mentioned earlier, they've got so much pressure that they're, as you described it, they're likely to interpret that early stage work as super high risky and potentially as, um, too high risk for failure.
- 37:45Is that right?
- 37:45That is spot on.
- 37:47So with federal funding, you know, uh, some of these grants have a five-year term.
- 37:52So you have five years to spend really getting into the weeds of all the nuances of these targets.
- 37:58When I worked in industry, they would, you would be assigned a program and within 18 months to two years you had to have the clinical candidate.
- 38:05So you threw an assay together pretty quickly that may or may not have been the, the best.
- 38:11And you drove on that 'cause you had to hit the milestone that get the metrics, but you didn't really understand necessarily the target as well as you should.
- 38:19Wow.
- 38:20And that's why in, in several, several of our programs, we've, we've, you know, been able to outpace big pharma'cause we just spent a lot more time understanding it.
- 38:30Amazing.
- 38:30And NIH enabled all that.
- 38:32Got it.
- 38:32So the National Institutes of Health, that investment, that infusion of federal funds, essentially as I hear you say, it, um, allowed you to do better science.
- 38:41Mm-hmm.
- 38:42Um, that actually ended up being more effective and more efficient in the long run.
- 38:46Much more thoughtful science.
- 38:49And having the time to just ask questions, you know: "What are the liabilities of this mechanism?
- 38:53How can we address those?
- 38:54Maybe we need to go into, you know, move from cells to native tissues and do electrophysiology.
- 38:58Maybe we need to do different types of animal models.
- 39:00Maybe we need to take compounds with very different profiles and, and, and put them in animals.
- 39:05And what does it, what does it look like?" And it's just things you in the industry.
- 39:08'cause it's just you have to, you got shareholders you're accountable to and you've got candidate metrics every year that management has to hit for the, you know...
- 39:17Yeah.
- 39:17I mean, for their position.
- 39:18So it's, it's, it's academics is the only one you can, and you're not really being leisurely, but you just have, you do have the benefit of time.
- 39:27Yeah.
- 39:28And your shareholders, it sounds like your shareholders are the American people.
- 39:32That's true.
- 39:33Yeah.
- 39:34I think it's just so interesting to think about and so important to think about, not simply interesting intellectually, but deeply important in terms of the way the machine works to lead to our ability to outpace other nations around the globe.
- 39:48And how we, um, inspire both the creativity and the competitiveness that your lab really, uh, uh, serves as such a great model for, you know.
- 39:58You're super creative, you're going after majorly difficult, uh, diseases like Alzheimer's, um, and Parkinson's, but you're also incredibly thorough.
- 40:06I love how you manage that and, you know, the extent to which you're doing that because you both embrace partnership with, uh, pharmaceutical firms, and you capitalize and use, um, so effectively that, uh, early, early-stage federal investment.
- 40:23And I think another really important point, doing this type of work in a university setting— all of our scientists are here.
- 40:31We're all in the same building.
- 40:33Uh, we talk daily, we're integrated.
- 40:36What you've seen in industry over the last 20 years is they outsource more and more work to foreign countries.
- 40:42They'll outsource chemistry.
- 40:43They'll outsource biology.
- 40:44They'll outsource behavior and drug metabolism.
- 40:47And they'll have one or two scientists at the company that are directing all these offshore work...
- 40:52Mm. I never thought of offshore work.
- 40:53...and there's not communication.
- 40:54Yeah.
- 40:54You don't have the communication and you, and you don't have leadership in all these areas talking daily, discussing the data and the implications of it and how to modify it and what we need to, you know, how we need to pivot.
- 41:07And it, you know, while they save money in the short term, it takes far longer to get to a clinical candidate than if they did it all internally.
- 41:14So if you think of a drug's gonna make a couple billion dollars a year, and it took you a few extra years to get there, you didn't save billions on the ... on the discovery.
- 41:23Yeah.
- 41:23But universities are just poised to be more successful just because we're in-house integrated teams.
- 41:29Fascinating.
- 41:30I mean, I never thought about us as in-house, right.
- 41:32That, um, we don't offshore our scientific discovery.
- 41:36We do that, all that work where you, Craig Lindsley, can walk the halls and check in on what's going on in, in that particular moment where things might be going a little sideways or things need to get out.
- 41:48Yeah.
- 41:48It's basically the pharmaceutical industry in the sixties and seventies, when they're probably the most successful.
- 41:53And we're still taking drugs today, developed in the sixties and seventies because of that tight- knit integration and close working interaction that, that that industry had, and they've moved away from that.
- 42:02Incredible.
- 42:03So in that way that you are then partnering with pharmaceuticals, how does that relationship work?
- 42:10Because you know, obviously that's a huge strength, I think, of American scientific enterprise, that we figure out how to accelerate the impact of the work that our scientists do by getting it out into the market, into the real world by partnering with corporations.
- 42:25How, tell me a little bit about that partnership.
- 42:27So it's been a great academic, uh, industrial kind of balance.
- 42:31So the early, all the papers on the early proof of concept studies are kind of the billboards for people to come, wanna come work with us. And then, all of our, I I, the industrial collaborations come in many different flavors. For most, most of them, uh, they fund us to do all the research here, and we agree on what a candidate would look like, the profile, and when we achieve that, uh, then they take it and do the development.
- 42:57We've had other, uh, with some other large pharmas, there's a, a research team there working on it as well.
- 43:02So the chemists from both sites have target meetings and interact all the time.
- 43:07Same thing on all, for all the other disciplines.
- 43:09Uh, and then we jointly develop the IP and, and get the compounds into the clinic.
- 43:13So it, it really kind of depends.
- 43:15Yeah.
- 43:16But what's been so great about it is like when, not just to pick on Merck, but when I worked at Merck, there's the Merck way of doing everything.
- 43:22It just, it was: "This is how we do it.
- 43:24It just, it was: This is the workflow, this is what you do." Having worked now with 37 different organizations, you kind of see how every company, based on their past experience does things a little differently.
- 43:34It just, it was: Wow.
- 43:35It just, it was: So you work with 37 different corporate entities.
- 43:37It just, it was: Mm-hmm.
- 43:38It just, it was: Amazing.
- 43:38It just, it was: And so now we, our workflow, like our, our internal Warren Center workflow, takes the best from all these different people.
- 43:44It just, it was: We've integrated it so it doesn't look like anything I've done before.
- 43:48It just, it was: And it's, it's the best of all worlds.
- 43:50It just, it was: And if you're working in a company for 30 years, you have no idea what the guy down the street is doing.
- 43:54It just, it was: We've got to see it all.
- 43:55It just, it was: We got to see under the hood of everybody and take all the best elements.
- 43:58It just, it was: And so when we start doing our early stage projects, now we're using these workflows that are really the, the, the best of what you'd see in pharma.
- 44:05It just, it was: And so we're able to get to compounds pretty quickly that they then garner interest from, you know, other companies and so on and so forth.
- 44:13It just, it was: Amazing.
- 44:13It just, it was: So you serve as this interesting hybridizing of the methods of science, not just of, um, the actual, you know, compounds that you discover.
- 44:23It just, it was: mm-hmm.
- 44:23It just, it was: You're, you're sharing processes of how to either manufacture or test, um, those candidates across all of those different corporate entities and across those different platforms.
- 44:35It just, it was: Is that something that's explicit?
- 44:36It just, it was: Like, "Hi, I am a new pharmaceutical company and I'd like my people to train with you, Craig. I'd like my people to be embedded in your research lab.
- 44:45It just, it was: And you know, two years from now, I'd like some of your people to be embedded in my corporate entity." Is there that kind of hybridizing?
- 44:52It just, it was: We've, we've done that as well.
- 44:53It just, it was: So with Ono, that collaboration started in 2012.
- 44:58It just, it was: The original collaboration was just they sent scientists here to work in the lab and see how we do things.
- 45:03It just, it was: Then it became a large, sponsored research program.
- 45:06It just, it was: And then during the course of that, they would usually send one or two chemists to work in our labs and a biologist to work on the labs with Jerod Denton on campus, and they would even send behavioral pharmacologists.
- 45:16It just, it was: Fascinating.
- 45:17It just, it was: So it it was great, you know, and also just the, the, the whole culture working with people all around the world, all across Europe and, and, and, and Asia.
- 45:25It just, it was: It's, it's just been, uh, it's been fascinating— just the the cultural exchange as well as the scientific exchange.
- 45:30It just, it was: Yeah, I'm sure.
- 45:30It just, it was: Just, it's just fantastic.
- 45:31It just, it was: "What're you having for lunch?" It's pretty awesome.
- 45:34It just, it was: "Do you work on Saturdays," right?
- 45:35It just, it was: I'm sure.
- 45:36It just, it was: Right?
- 45:36It just, it was: Mm-hmm.
- 45:37It just, it was: ' And I guess that's really, I think, That I think about executive education, for example, in business.
- 45:44It just, it was: That, you know, corporate entities send some of their mid-career executives, their leaders to a university like ours to learn more about how to run the business effectively.
- 45:54It just, it was: But I don't often think about scientists in the, you know, pharmaceutical industry or in the drug discovery industry outside of universities as also sending their mid-career team to learn, that there, there is that exchange, um, in terms of training, not just in terms of intellectual property.
- 46:11It just, it was: Really exciting.
- 46:13It just, it was: And, you know, you just touched on property too.
- 46:15It just, it was: Different companies in different regions of the world's approach patent filings very differently.
- 46:21It just, it was: Hmm.
- 46:21It just, it was: And so that's also been a real educational process to see how everyone just approaches it so fundamentally differently.
- 46:28It just, it was: Right?
- 46:28It just, it was: How do we claim credit?
- 46:29It just, it was: How do we And when?
- 46:30It just, it was: And how?
- 46:31It just, it was: There's just How do we earn?
- 46:33It just, it was: Yeah.
- 46:34It just, it was: It's just really interesting.
- 46:35It just, it was: Fascinating.
- 46:35It just, it was: And did you know, you were always, I mean, when you were six, you know, sitting at the kitchen table, I have no idea what you had for breakfast.
- 46:42It just, it was: But when you were sitting there, you know, prior to heading off to school, you know, first grade, did you know that you were gonna be, you know, a leader in drug discovery?
- 46:51It just, it was: What, what was... Oh, no.
- 46:53It just, it was: ...what was the path that you followed to get here, Craig?
- 46:55It just, it was: Let's see, six years old.
- 46:55It just, it was: Star Wars came out.
- 46:56It just, it was: I think I wanted to be Luke Skywalker, but, um, that didn't work out.
- 47:00It just, it was: All right.
- 47:00It just, it was: Uh, so you're not an astronaut?
- 47:02It just, it was: No, I actually, when I started college, I started off as an English major.
- 47:05It just, it was: Wow.
- 47:06It just, it was: Um, for all our English majors.
- 47:08It just, it was: Yeah.
- 47:08It just, it was: And, um.
- 47:09It just, it was: I ended up taking chemistry classes and took organic chemistry and it just, it that just all made sense.
- 47:17It just, it was: Wow.
- 47:18It just, it was: Ended up getting a minor in English, which has been so helpful.
- 47:20It just, it was: 'cause you know, I think one of the biggest things with scientists is being able to, uh, communicate orally and, and, and, and written and, um.
- 47:28It just, it was: All we do is write papers and patents and grants, and if you're not a good writer and you can't tell a compelling story and intertwine the, the data in the story...
- 47:36It just, it was: Right.
- 47:37It just, it was: Right.
- 47:37It just, it was: Scientists are writers.
- 47:38It just, it was: ...you're not gonna be funded.
- 47:38It just, it was: So it's Absolutely.
- 47:40It just, it was: So, you know, I think it was a, it was a very good call.
- 47:42It just, it was: That's great.
- 47:43It just, it was: And did you have a chance to be in, you know, the sort of standard track of graduate school and then a postdoc...
- 47:50It just, it was: Mm-hmm.
- 47:50It just, it was: ...in somebody else's lab and then you went to Merck from there?
- 47:53It just, it was: Mm-hmm.
- 47:54It just, it was: Got it.
- 47:54It just, it was: Yeah.
- 47:55It just, it was: Ph.D., postdoc and then industry for 10 years and then came here.
- 48:00It just, it was: And how do you explain to your family or your community, um, what you do?
- 48:04It just, it was: Do they get it?
- 48:05It just, it was: Yeah, I think they get it at a very high level.
- 48:07It just, it was: We're we're, you know, they think we're, you know, we're trying to make fundamentally new drugs for various, you know, brain disorders and for brain health.
- 48:17It just, it was: And, uh, it's hard and it's challenging and, um.
- 48:20It just, it was: You know, just like with, you know, everyone knows someone that, that family with cancer.
- 48:25It just, it was: It's amazing as you start talking to more people, and I think as the population's getting older, everyone I know has someone in their family suffering from Alzheimer's or Parkinson's.
- 48:36It just, it was: Absolutely.
- 48:37It just, it was: And actually schizophrenia, which is surprising to me that because it's, it's somewhat rare, but this the, the number of times people say, "oh, my sister or my mother," and it's, it's surprising.
- 48:46It just, it was: Yeah.
- 48:47It just, it was: Well, and I think some of it probably is because of the way in which we're getting better at diagnosing, right?
- 48:52It just, it was: So.
- 48:53It just, it was: Perhaps before we said, "Oh, somebody's aging and they're getting forgetful, or they're becoming difficult to manage." Mm-hmm.
- 49:00It just, it was: Um, but now we're clearer about that being a neurodegenerative disease, and that that's something that is happening in their brains that's atypical and needs, needs care.
- 49:11It just, it was: And I think finally the stigma is, is not as as great as it used to be.
- 49:15It just, it was: And, and one thing we talk about all the time is brain health and brain disorders.
- 49:18It just, it was: We're not really talking about mental health,'cause it's the negative connotations of that.
- 49:22It just, it was: Yes.
- 49:22It just, it was: And I think more and more people, even adolescents, are asking for help and telling people when they're struggling or having problems.
- 49:27It just, it was: So it's...
- 49:28It just, it was: we're finding it out sooner and being able to hopefully have interventions earlier.
- 49:33It just, it was: And I love that your lab is committed to that, to some of that communication effort.
- 49:37It just, it was: Mm-hmm.
- 49:38It just, it was: Um, whether it's inspired by your English interests or in your prior experience just communicating to a broader community, um, that brain health is, you know, a key area that people deserve to be able to pursue the health of...
- 49:52It just, it was: Mm-hmm.
- 49:53It just, it was: ...their cognitive function, their emotional function, um, their, their sleep, their well-being.
- 49:59It just, it was: I think, I think it's helped a lot too when you have folks like Michael J. Fox being so public about it.
- 50:04It just, it was: It's really helped.
- 50:05It just, it was: And, and then for other disorders and disease as well, more and more people are coming out and talking about things. And you know, like, and, and there's sympathy for it now, which I think is so important.
- 50:14It just, it was: 'cause you know, for a while if you had a a brain disorder, people treated you differently and looked down on you. And you would not look down on somebody that had cancer or...
- 50:24It just, it was: Right.
- 50:24It just, it was: ...or something, you know?
- 50:25It just, it was: It's just, it's just really interesting.
- 50:26It just, it was: Not a source of shame, but instead a source of seeking help.
- 50:29It just, it was: Absolutely.
- 50:31It just, it was: Amazing conversation so far, Craig.
- 50:33It just, it was: I'm so grateful for being able to kind of have you explain so much of the intricacies of the work that you do.
- 50:39It just, it was: If there's one message that you wanted our listeners to take away, what would it be?
- 50:44It just, it was: Well, I think where we are right now— I'm not trying to be political—but just in general where we are right now and, and the, the damage that's being done to universities and the, the, the NIH.
- 50:54It just, it was: It's gonna be a big detriment to, to discovery and, and developing new therapeutics in the future. We're gonna have, with things that are going on, I really worry that you're gonna, you're gonna have a gap in, in people coming in that can do the work we're doing now.
- 51:08It just, it was: Yeah.
- 51:08It just, it was: Um, that's a big concern for me.
- 51:10It just, it was: And can you say just a little bit more about kind of the ripple effects of that concern?
- 51:14It just, it was: You know, if we didn't do work for the next two years in your lab, if your lab had to take a pause—what would be the downstream effects, whether it's for, Franklin, Tennessee, or for the scientists in your lab or for people like me who have a friend or a family member with Alzheimer's or another neurodegenerative disease?
- 51:34It just, it was: Well, I obviously any kind of pause, uh, is gonna delay things moving forward.
- 51:39It just, it was: And then you're also burning patent life during the course of that time, and then that makes the products less attractive to companies 'cause they've lost more, less of their exclusivity time.
- 51:49It just, it was: It's just, um...
- 51:51It just, it was: So wait, that's interesting.
- 51:52It just, it was: Delays are exponential.
- 51:54It just, it was: Delays are exponential, and you just described delays in the business sector.
- 51:58It just, it was: Mm-hmm.
- 51:58It just, it was: That the intellectual property doesn't hold its value in perpetuity.
- 52:03It just, it was: It's not like a.
- 52:04It just, it was: No.
- 52:04It just, it was: You get a set time for, you get 22 years of, of patent life when you file a case.
- 52:08It just, it was: And if, if it sits idle for years, uh, you don't get that time back.
- 52:12It just, it was: And then, you know, industry can view those as damaged goods.
- 52:15It just, it was: 'cause well now.
- 52:16It just, it was: You know, if, if it does take 15 years to get to market, we're hoping to have seven years of exclusive sales to recoup all the, for all the programs that failed.
- 52:25It just, it was: And so, you know, delays, multi-year delays, the value of that asset dropped and dropped.
- 52:30It just, it was: No matter how good the molecule is, no matter how impactful it could be, there's not that financial gain at the end, so they may not license it and develop it.
- 52:37It just, it was: Wow.
- 52:38It just, it was: And what about loss of optimism or belief in doing science?
- 52:43It just, it was: Do you think that...
- 52:43It just, it was: That's even more concerning.
- 52:44It just, it was: Because as, as students, like you've seen, a lot of universities are rescinding graduate student offers that have already been made.
- 52:52It just, it was: They're not accepting students this year.
- 52:54It just, it was: And then at NIH in the intramural program, one of my former students on a Saturday, they got an email that their tenure track jobs were terminated and they had to be out by ... Sunday.
- 53:04It just, it was: And you know, so you're just having a whole generation of, a whole generation of people that are very talented and very capable now looking to leave science.
- 53:11It just, it was: I don't know how you're ever gonna rebuild the intramural program at the federal government 'cause there's no stability. And, and there's little stability already in industry, and there's...
- 53:23It just, it was: Right.
- 53:24It just, it was: It's, we're, you're gonna face it— why would people want to go into science?
- 53:29It just, it was: It's hard, right?
- 53:30It just, it was: The thing you just described is so hard.
- 53:32It just, it was: And the training to get there is so it takes so long.
- 53:34It just, it was: Right?
- 53:35It just, it was: And then if you're in a position where, you know, any one, uh, administration can just change everything and eliminate all.
- 53:43It just, it was: I mean, it's just, it's really scary.
- 53:45It just, it was: It's, it's scary for the world.
- 53:47It just, it was: I hear you and you know, I think the flip side is that I see you and your team figuring out a way to really maximize every dollar invested, whether that's a federal dollar invested two years ago, or a federal dollar invested yesterday or a uh, you know, corporate dollar or a philanthropic dollar—that you're really, uh, pushing hard on the value of every one of those dollars invested.
- 54:15It just, it was: And, you know, I, I remain hopeful that we will find means of, um, trying to secure as much of that support as we can because it is so incredibly valuable.
- 54:27It just, it was: I'm so deeply appreciative of the kind of commitment that you make, but that all of those 26 people make. Mm-hmm.
- 54:33It just, it was: That all of those, uh, other 40 people that support those 26 people, right.
- 54:37It just, it was: That, that, that, uh, amazing group continues to really thrive and flourish.
- 54:42It just, it was: Well, thank you.
- 54:42It just, it was: I think, you know, the, the, the folks at the Warren Center are just some of the best.
- 54:45It just, it was: They're the best scientists.
- 54:46It just, it was: They're the most dedicated people you're ever gonna meet.
- 54:48It just, it was: Dr. Lindsley, this has been such a fascinating conversation.
- 54:53It just, it was: For those who listen, um, believing in the importance of neuroscience research is really, um, clear, I think from this conversation.
- 55:00It just, it was: What actions would you want us all to take as we move forward?
- 55:04It just, it was: You know, support scientists, support the folks that are out there trying to make a difference and impact, you know, the lives of your, you know, your family members.
- 55:12It just, it was: You know, be kind.
- 55:13It just, it was: People are struggling.
- 55:14It just, it was: Brain health is a, is a, is...
- 55:16It just, it was: issues are growing exponentially.
- 55:18It just, it was: And, um, you know, people need care and, um, compassion.
- 55:24It just, it was: And hopefully there'll be new therapeutics on the market soon that will, uh, really change their quality of life and their families'.
- 55:29It just, it was: I love that.
- 55:30It just, it was: I love that.
- 55:31It just, it was: You know, something as dry as chemistry leads us to care and compassion.
- 55:36It just, it was: Yeah.
- 55:37It just, it was: Really inspiring.
- 55:38It just, it was: Really fascinating, Craig.
- 55:39It just, it was: Thank you so much for taking the time.
- 55:42It just, it was: I really wanna applaud you for not only, uh, protecting our nation's health, but really serving as a galvanizing force in American enterprise.
- 55:50It just, it was: And, um, it's just really exciting to see where the Warren Center and where your own leadership will go.
- 55:56It just, it was: Thanks to our listeners for tuning in.
- 55:58It just, it was: Remember to stay curious and keep exploring new ideas.
- 56:02It just, it was: We'll be back next time with another guest who's pushing the boundaries of discovery.
- 56:06It just, it was: Until then, I'm Cybele Raver, and this is 'Quantum Potential.' The 'Quantum Potential' podcast comes from Vanderbilt University.
- 56:23It just, it was: Your host is C. Cybele Raver.
- 56:26It just, it was: Thank you to our guest, Craig Lindsley.
- 56:30It just, it was: Production by Matriarch Digital Media.
- 56:33It just, it was: For more information about'Quantum Potential,' go to vanderbilt.edu/quantumpotential.
- 56:42It just, it was: Stay curious.